News|Videos|November 13, 2023
MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC
Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
Advertisement
Episodes in this series
Advertisement
Related to this article
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Behind the FDA Approval of Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
PRV111 Shows Strong Responses in Early Oral Cancer
5